new Delhi11 minutes ago
- Copy link
The Sputnik V vaccine has been created by the Russian Direct Investment Fund and the Gamalaya Scientific Research Institute of Epidemology. -File photo
- On September 16, the Russian Direct Investment Fund and Dr. Reddy agreed to a trial in India.
- Sputnik V vaccine has been prepared by Gamalaya Research Institute of Epidemology.
India has received approval for the second and third phase clinical trials of the Russian vaccine Sputnik V. The Drug Controller General of India (DCGI) has allowed the trial. The trial will be able to detect the impact of the vaccine on a large scale in the country. On 16 September, the Russian Direct Investment Fund (RDIF) and Dr. Reddy agreed to the trial and distribution of Sputnik V in India.
Dr. Reddy’s Laboratory Co-Chairman and MD G.V. “This is an important development, which allows us to start clinical trials in India,” Prasad said in a statement. We are committed to bring a safe and effective vaccine to combat the epidemic. ”
Vaccine delivery may end by 2020
Earlier, RDIF said that 100 million doses of vaccine would be supplied to Dr. Reddy, a Hyderabad-based company in India. The Sputnik vaccine is based on the adenoviral vector platform, which is undergoing trials to prevent coronavirus epidemics. It was also said that the delivery of the vaccine in India is likely to begin by the end of 2020, after successful trials and registration is completed.
The Sputnik V vaccine has been created by the Russian Direct Investment Fund and the Gamalaya Scientific Research Institute of Epidemology. It was registered on 11 August.